SCHEMBL20119633

SCHEMBL20119633

OCCn1cnc2c(NCc3ccco3)ncnc21

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.67
CDK1 P06493 3/20 0.64
CCNB2 O95067 2/20 0.64
CCNB1 P14635 2/20 0.64
CCNB3 Q8WWL7 2/20 0.64
TP53 P04637 3/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
PAX8 Q06710 2/20 0.58
ADORA3 P0DMS8 2/20 0.58
SLC29A1 Q99808 1/20 0.58
MITF O75030 1/20 0.58
LMNA P02545 1/20 0.58
ADORA2A P29274 3/20 0.52
ADORA1 P30542 3/20 0.52
TMIGD3 P0DMS9 1/20 0.52
ADORA2B P29275 1/20 0.50
RAB9A P51151 3/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 2/20 0.48
NPC1 O15118 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL457250 0.88 HTT (0.67) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL457947 0.88 HTT (0.70) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL15167431 0.86 HTT (0.67) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL20097160 0.86 CCNB2 (0.69) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL15167412 0.85 HTT (0.63) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL31711717 0.84 HTT (0.61) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL31711723 0.84 HTT (0.61) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL20119392 0.83 CDK1 (0.53) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL20119629 0.83 CDK1 (0.72) HTTCDK1CCNB2CCNB1CCNB3
SCHEMBL31711719 0.83 HTT (0.60) HTTCDK1CCNB2CCNB1CCNB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HTT 326/4885CDK1 3620/4885CCNB2 4151/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HTT 326/4885CDK1 3620/4885CCNB2 4151/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HTT 326/4885CDK1 3620/4885CCNB2 4151/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HTT 326/4885CDK1 3620/4885CCNB2 4151/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HTT 326/4885CDK1 3620/4885CCNB2 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.